23andMe SPAC Presentation Deck

We Are Rapidly Scaling Our Therapeutics Discovery Efforts Note: Fiscal year ends March 31.¹ Based on internal modeled estimates subject to scientific, development and compliance risks. Includes collaborated, 100% owned and royalty interests targets and adjusted for probability of technical success. Accelerating Number of Validated Targets¹ 2 FY19A 8 FY20A 18 FY21E 25 FY22E 31 FY23E 37 FY24E 23and Me Confidential and Proprietary Information 30

View entire presentation